Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma
Clin. transl. oncol. (Print)
; 24(6): 1014-1032, junio 2022.
Article
in En
| IBECS
| ID: ibc-203803
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Esophageal cancer is a complex gastrointestinal malignancy with an extremely poor outcome. Approximately 80% of cases of this malignancy in Asian countries including India are of squamous cell origin, termed Esophageal Squamous Cell Carcinoma (ESCC).The five-year survival rate in ESCC patients is less than 20%. Neo-adjuvant chemo-radiotherapy (NACRT) followed by surgical resection remains the major therapeutic strategy for patients with operable ESCC. However, resistance to NACRT and local recurrence after initial treatment are the leading cause of dismal outcomes in these patients. Therefore, an alternative strategy to promote response to the therapy and reduce the post-operative disease recurrence is highly needed. At the molecular level, wide variations have been observed in tumor characteristics among different populations, nevertheless, several common molecular features have been identified which orchestrate disease progression and clinical outcome in the malignancy. Therefore, determination of candidate molecular pathways for targeted therapy remains the mainstream idea of focus in ESCC research. In this review, we have discussed the key signaling pathways associated with ESCC, i.e., Notch, Wnt, and Nrf2 pathways, and their crosstalk during disease progression. We further discuss the recent developments of novel agents to target these pathways in the context of targeted cancer therapy. In-depth research of the signaling pathways, gene signatures, and a combinatorial approach may help in discovering targeted therapy for ESCC.
Key words
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Esophageal Neoplasms
/
Cell Line, Tumor
/
Esophageal Squamous Cell Carcinoma
Limits:
Humans
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2022
Document type:
Article